Rheumatology in the digital health era: status quo and quo vadis?

Autor: Knitza J; Institute for Digital Medicine, University Hospital of Giessen and Marburg, Marburg, Germany. knitza@uni-marburg.de., Gupta L; Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK., Hügle T; Department of Rheumatology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Jazyk: angličtina
Zdroj: Nature reviews. Rheumatology [Nat Rev Rheumatol] 2024 Dec; Vol. 20 (12), pp. 747-759. Date of Electronic Publication: 2024 Oct 31.
DOI: 10.1038/s41584-024-01177-7
Abstrakt: Rheumatology faces a critical shortage of health-care professionals, exacerbated by an ageing patient population and escalating costs, resulting in widening gaps in care. Exponential advances in digital health technologies (DHTs) in the past 5 years offer new opportunities to address these challenges and could contribute to overall improved health care. However, keeping pace with innovations and integrating them into clinical practice can be challenging. This Review explores the transformative potential of DHTs for rheumatology in reshaping the entire patient pathway and redefining the roles of patients and providers, and discusses the potential barriers to DHT integration. Key technologies, such as large language models, clinical decision-support systems, digital therapeutics, electronic patient-reported outcomes, digital biomarkers, robots, self-sampling devices and artificial intelligence-based scribes, can be implemented along the patient pathway. A digital-first hybrid stepped-care patient pathway could combine in-person and remote care, enabling personalized and continuous monitoring through a digital safety net. The potential benefits and risks of transforming the traditional patient-provider relationship into a digital health triad with technology are discussed. Collaborative efforts are needed to navigate the evolving digital health landscape and harness the potential of DHTs to improve rheumatology care.
Competing Interests: Competing interests: J.K. declares research support from Abbvie, BMBF, EIT Health, GSK, Sanofi and Vila Health, and honoraria and consulting fees from Abbvie, AstraZeneca, BMS, Boehringer Ingelheim, Chugai, GAIA, Galapagos, GSK, Janssen, Lilly, Medac, Novartis, Pfizer, Sobi, Rheumaakademie, UCB, Vila Health and Werfen. T.H. declares research support from Fresenius Kabi, Eli Lilly and Pfizer, and honoraria and consulting fees from Roche, Novartis, BMS, Eli Lilly, Janssen, UCB, Pfizer and Werfen. T.H. holds patents with and is a board member of Atreon and Vtuls. L.G. declares no competing interests.
(© 2024. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: